Abstract: This disclosure relates to the treatment of subjects at risk for chronic kidney disease (CKD), having stage one to five CKD, having hyperphosphataemia, susceptible to or suffering from soft tissue calcification associated with CKD, or susceptible to or suffering from hyperparathyroidism, by orally administering a pharmaceutical composition containing a therapeutically effective amount of lanthanum hydroxycarbonate.

Abstract: Stabilized lanthanum carbonate compositions containing a monosaccharide or disaccharide stabilizing agent are disclosed. Subjects having hyperphosphatemia can be treated by administering a pharmaceutical composition containing a therapeutically effective amount of the stabilized lanthanum carbonate formulation.

Abstract: This invention relates to a chewable lanthanum formulation comprising a pharmaceutically effective amount of a lanthanum compound; and at least one chewable pharmaceutically acceptable excipient. This invention also relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; or b) powder blending the lanthanum compound and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and c)compressing the resulting mixture into a tablet or filing up the resulting mixture in a appropriate container.